Leadership Team

When it comes to finding a cure for neurodegenerative diseases, our team won’t take no for an answer. Progress is made possible thanks to the passion and drive of every Amylyx team member.

Executive Team

Debra Canner
Debra CannerGlobal Head of Human Resources & CHRO
Debra Canner

Meet Debra Canner

Global Head of Human Resources & CHRO

Debra Canner joined Amylyx in 2019 as Global Head of Human Resources, and she currently oversees all human resources efforts. During her distinguished career she has held chief human resources officer roles at several preeminent life sciences and technology organizations, including Akamai Technologies, Joslin Diabetes Center, and Haemonetics Corporation. Earlier in her career, she served as Vice President of Human Resources, at Genzyme. Debra received a Bachelor of Arts from the University of Massachusetts, Amherst, and she holds a certification in Executive Leadership Development from the Center for Creative Leadership.

Visit Debra’s LinkedIn profile to learn more
Josh Cohen
Josh CohenCo-CEO & Co-Founder
Josh Cohen

Meet Josh Cohen

Co-CEO & Co-Founder

Josh Cohen co-founded Amylyx Pharmaceuticals in 2013 and has served since that time as its Co-CEO, its Co-Founder, and as Chairman of the board of directors. Josh co-invented AMX0035 and has overseen the growth of Amylyx from its start as a concept dreamed up in a dorm room to its status now as a pre-commercial stage pharmaceutical company. Together with Justin, Josh has raised nearly $250M in financing to support the development of new therapies for ALS and other neurodegenerative diseases. Josh received his Bachelor of Science in Biomedical Engineering from Brown University.

Visit Josh’s LinkedIn profile to learn more
James Frates
James M. FratesChief Financial Officer
James Frates

Meet James M. Frates

Chief Financial Officer

Jim Frates serves as Amylyx’s Chief Financial Officer, having previously been the CFO of Alkermes for 22 years. Prior to working at Alkermes, Jim was a Vice President in the Life Sciences Practice at Robertson Stephens & Company. He currently serves on the board of directors of Sage Therapeutics and is a Trustee of St. Francis House, the largest homeless day shelter in Massachusetts. Jim earned a Bachelor of Arts in Government from Harvard College and a Master of Business Administration from the Harvard Graduate School of Business Administration.

Visit Jim’s LinkedIn profile to learn more
Tom Holmes
Tom HolmesGlobal Head of Supply Chain
Tom Holmes

Meet Tom Holmes

Global Head of Supply Chain

Tom Holmes joined Amylyx in 2019 as Global Head of Supply Chain, bringing to the company more than 25 years of leadership experience in supply chain, biopharmaceutical manufacturing, and program management. Prior to joining Amylyx, Tom was the Senior Director of External Manufacturing at Biogen Inc., a role he held for 10 years. Tom received a Bachelor of Science in Business Administration with a concentration in Management from Salem State University.

Visit Tom’s LinkedIn profile to learn more
Justin Klee
Justin KleeCo-CEO & Co-Founder
Justin Klee

Meet Justin Klee

Co-CEO & Co-Founder

Justin Klee co-founded Amylyx Pharmaceuticals in 2013 and continues to serve as its Co-CEO and Co-Founder. Justin has overseen the development of Amylyx’s novel platform and therapeutic for neurodegenerative diseases from initial testing through clinical trials. Justin previously did research in neural systems while at Brown University and in neurophysiology and Alzheimer’s disease at Harvard Medical School. He received his Bachelor of Science in Neuroscience from Brown University.

Visit Justin’s LinkedIn profile to learn more
Margaret Olinger
Margaret OlingerGlobal Head of Commercial & CCO
Margaret Olinger

Meet Margaret Olinger

Global Head of Commercial & CCO

Margaret Olinger joined Amylyx in 2019 as the Global Head of Commercial/Chief Commercial Officer, bringing with her more than 30 years of commercial experience in the pharmaceutical industry. Margaret joins us from Alexion Pharmaceuticals, where she worked for more than a decade and for whom she led the global commercial launch of Soliris and Strensiq. Margaret helped build and lead highly successful commercial launches and operations for therapies addressing unmet needs in rare and ultra-rare diseases. Prior to working at Alexion, Margaret spent nearly 20 years at Bayer Healthcare, serving in various leadership and commercial positions. She received a Bachelor of Science in Business Administration from Albertus Magnus College and a Master of Business Administration from the University of New Haven.

Visit Margaret’s LinkedIn profile to learn more
Patrick Yeramian
Patrick Yeramian, MD, MBAGlobal Head of Clinical R&D & CMO
Patrick Yeramian

Meet Patrick Yeramian, MD, MBA

Global Head of Clinical R&D & CMO

Dr. Yeramian joined Amylyx as Chief Medical Officer in 2019, bringing to the company more than 30 years of pharmaceutical industry experience. He was previously the consulting Medical Director for Amylyx, where he supported the pre-IND and IND filings of AMX0035. Before his time at Amylyx, he served as Chief Medical Officer for several emerging pharmaceutical and biotechnology companies, including Viragen, Transmolecular, Tapimmune, and Biovie. He also served as the Medical Director for the Vaccine and Gene Therapy Institute of Florida. Throughout his career, Dr. Yeramian has held prominent roles in the approval of several drug applications by the FDA and EMA and more than 20 successful INDs and IMPDs. He holds a Medical Degree from the University of Paris, together with a Master of Clinical Science in experimental oncology and a graduate degree in molecular virology. He received his Master of Business Administration from Rutgers University and completed his medical residency in oncology at the Saint-Louis Hospital in Paris.

Visit Patrick’s LinkedIn profile to learn more

Lead Scientific Advisor

Rudolph Tanzi, Ph.D.
Rudolph Tanzi, PH.D.Founding Chair of the Amylyx SAB
Rudolph Tanzi, Ph.D.

Meet Rudolph Tanzi, PH.D.

Founding Chair of the Amylyx SAB

Dr. Rudolph Tanzi serves as the Founding Chairman of Amylyx’s Scientific Advisory Board. He is an acclaimed researcher and a New York Times best-selling author, and GQ Magazine dubbed him a “Rock Star of Science.” Over the course of his impressive career, Dr. Tanzi has discovered several neurological disease genes and has received the highest awards in his field. He has also been acknowledged by Time magazine’s Most Influential People in the World list. Today he directs the Alzheimer’s Genome Project and serves as the Vice Chair of Neurology, the Director of the Genetics and Aging Research Unit, and the Co-Director of the McCance Center for Brain Health at Massachusetts General Hospital. He also serves as the Joseph P. and Rose F. Kennedy Professor of Neurology at Harvard Medical School. He received his Bachelor of Science in Microbiology and his Bachelor of Arts in History from the University of Rochester, and he received his Doctorate in Neurobiology from Harvard Medical School.

Visit Rudolph’s LinkedIn profile to learn more

QUESTIONS?

For inquiries or further information, please do not hesitate to contact us.

Contact Us

Stay Connected

Get the latest news and updates from Amylyx, delivered right to your inbox.

By clicking SUBMIT, you confirm that you have read Amylyx's Privacy Policy and that you agree to receive the electronic communications from Amylyx that you've selected. You can withdraw your consent at any time.

Stay Connected

Get the latest news and updates from Amylyx, delivered right to your inbox.

By clicking SUBMIT, you confirm that you have read Amylyx's Privacy Policy and that you agree to receive the electronic communications from Amylyx that you've selected. You can withdraw your consent at any time.